

DUPONT E I DE NEMOURS & CO  
Form 10-Q  
July 24, 2012  
Table of Contents

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT  
OF 1934

For the quarterly period ended June 30, 2012

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT  
OF 1934

Commission File Number 1-815

E. I. du Pont de Nemours and Company  
(Exact Name of Registrant as Specified in Its Charter)

Delaware

(State or other Jurisdiction of  
Incorporation or Organization)

1007 Market Street, Wilmington, Delaware 19898  
(Address of Principal Executive Offices)

51-0014090  
(I.R.S. Employer  
Identification No.)

(302) 774-1000

(Registrant's Telephone Number)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that registrant was required to submit and post such files.) Yes  No

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of "large accelerated filer," "accelerated filer," and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large Accelerated Filer

Accelerated Filer

Non-Accelerated Filer

Smaller reporting company

Indicate by check mark whether the Registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act).  
Yes  No

The Registrant had 930,373,000 shares (excludes 87,041,000 shares of treasury stock) of common stock, \$0.30 par value, outstanding at July 16, 2012.

---

Table of Contents

## E. I. DU PONT DE NEMOURS AND COMPANY

## Table of Contents

The terms “DuPont” or the “company” as used herein refer to E. I. du Pont de Nemours and Company and its consolidated subsidiaries, or to E. I. du Pont de Nemours and Company, as the context may indicate.

	Page
<u>Part I</u>	<u>Financial Information</u>
<u>Item 1.</u>	<u>Consolidated Financial Statements (Unaudited)</u>
	<u>Consolidated Income Statements</u> 3
	<u>Consolidated Statements of Comprehensive Income</u> 4
	<u>Condensed Consolidated Balance Sheets</u> 5
	<u>Condensed Consolidated Statements of Cash Flows</u> 6
	<u>Notes to the Consolidated Financial Statements</u>
	<u>Note 1. Summary of Significant Accounting Policies</u> 7
	<u>Note 2. Other Income, Net</u> 7
	<u>Note 3. Provision for Income Taxes</u> 7
	<u>Note 4. Earnings Per Share of Common Stock</u> 8
	<u>Note 5. Inventories</u> 8
	<u>Note 6. Goodwill and Other Intangible Assets</u> 9
	<u>Note 7. Commitments and Contingent Liabilities</u> 9
	<u>Note 8. Stockholders’ Equity</u> 12
	<u>Note 9. Financial Instruments</u> 14
	<u>Note 10. Long-Term Employee Benefits</u> 19
	<u>Note 11. Segment Information</u> 19
<u>Item 2.</u>	<u>Management’s Discussion and Analysis of Financial Condition and Results of Operations</u> 21
	<u>Cautionary Statements About Forward-Looking Statements</u> 21
	<u>Results of Operations</u> 21
	<u>Segment Reviews</u> 23
	<u>Liquidity &amp; Capital Resources</u> 26
	<u>Contractual Obligations</u> 27
	<u>PFOA</u> 27
<u>Item 3.</u>	<u>Quantitative and Qualitative Disclosures About Market Risk</u> 27
<u>Item 4.</u>	<u>Controls and Procedures</u> 28
<u>Part II</u>	<u>Other Information</u>
<u>Item 1.</u>	<u>Legal Proceedings</u> 29
<u>Item 1A.</u>	<u>Risk Factors</u> 30
	<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>
<u>Item 2.</u>	30
<u>Item 4.</u>	<u>Mine Safety Disclosures</u> 30
<u>Item 6.</u>	<u>Exhibits</u> 30
<u>Signature</u>	31



Table of Contents

## PART I. FINANCIAL INFORMATION

## Item 1. CONSOLIDATED FINANCIAL STATEMENTS

## E. I. du Pont de Nemours and Company

## Consolidated Income Statements (Unaudited)

(Dollars in millions, except per share)

	Three Months Ended		Six Months Ended	
	June 30,		June 30,	
	2012	2011	2012	2011
Net sales	\$11,006	\$10,264	\$22,236	\$20,298
Other income, net	277	229	303	254
Total	11,283	10,493	22,539	20,552
Cost of goods sold and other operating charges	7,815	7,191	15,342	14,022
Selling, general and administrative expenses	1,186	1,136	2,355	2,163
Research and development expense	528	462	1,033	861
Interest expense	117	115	231	215
Total	9,646	8,904	18,961	17,261
Income before income taxes	1,637	1,589	3,578	3,291
Provision for income taxes	449	360	890	618
Net income	1,188	1,229	2,688	2,673
Less: Net income attributable to noncontrolling interests	9	11	21	24
Net income attributable to DuPont	\$1,179	\$1,218	\$2,667	\$2,649
Basic earnings per share of common stock	\$1.26	\$1.31	\$2.85	\$2.85
Diluted earnings per share of common stock	\$1.25	\$1.29	\$2.82	\$2.80
Dividends per share of common stock	\$0.43	\$0.41	\$0.84	\$0.82

See Notes to the Consolidated Financial Statements beginning on page 7.

Table of Contents

E. I. du Pont de Nemours and Company  
 Consolidated Statements of Comprehensive Income (Unaudited)  
 (Dollars in millions, except per share)

	Three Months Ended		Six Months Ended		
	June 30,		June 30,		
	2012	2011	2012	2011	
Net income	\$1,188	\$1,229	\$2,688	\$2,673	
Other comprehensive income (loss), before tax:					
Cumulative translation adjustment	(412	)73	(242	)117	
Net revaluation and clearance of cash flow hedges to earnings:					
Additions and revaluations of derivatives designated as cash flow hedges	38	(5	)36	3	
Clearance of hedge results to earnings	(23	)25	(55	)52	
Net revaluation and clearance of cash flow hedges to earnings	15	20	(19	)55	
Pension benefit plans:					
Net gain (loss)	4	(3	)19	(3	)
Prior service cost	—	(2	)22	(2	)
Reclassifications to net income:					
Amortization of prior service cost	3	4	7	8	
Amortization of loss	220	153	439	306	
Pension benefit plans, net	227	152	449	309	
Other benefit plans:					
Reclassifications to net income:					
Amortization of prior service benefit	(30	)31	(60	)61	)
Amortization of loss	22	15	44	30	
Other benefit plans, net	(8	)16	(16	)31	)
Net unrealized gain (loss) on securities	1	(1	)2	—	
Other comprehensive income (loss), before tax	(177	)228	174	450	
Income tax expense related to items of other comprehensive income	(76	)54	(140	)116	)
Other comprehensive income (loss), net of tax	(253	)174	34	334	
Comprehensive income	935	1,403	2,722	3,007	
Less: Comprehensive income attributable to noncontrolling interests	34	9	48	21	
Comprehensive income attributable to DuPont	\$901	\$1,394	\$2,674	\$2,986	

See Notes to the Consolidated Financial Statements beginning on page 7.

Table of Contents

E. I. du Pont de Nemours and Company  
 Condensed Consolidated Balance Sheets (Unaudited)  
 (Dollars in millions, except per share)

	June 30, 2012	December 31, 2011
Assets		
Current assets		
Cash and cash equivalents	\$3,506	\$3,586
Marketable securities	50	433
Accounts and notes receivable, net	9,476	6,022
Inventories	6,011	7,195
Prepaid expenses	151	151
Deferred income taxes	932	671
Total current assets	20,126	18,058
Property, plant and equipment, net of accumulated depreciation (June 30, 2012 - \$19,962; December 31, 2011 - \$19,349)	13,342	13,412
Goodwill	5,348	5,413
Other intangible assets	5,228	5,413
Investment in affiliates	1,087	1,117
Deferred income taxes	3,822	4,067
Other assets	1,078	1,012
Total	\$50,031	\$48,492
Liabilities and Equity		
Current liabilities		
Accounts payable	\$3,695	\$4,816
Short-term borrowings and capital lease obligations	3,696	817
Income taxes	930	255
Other accrued liabilities	4,117	5,297
Total current liabilities	12,438	11,185
Long-term borrowings and capital lease obligations	11,254	11,736
Other liabilities	14,643	15,508
Deferred income taxes	1,051	1,001
Total liabilities	39,386	39,430
Commitments and contingent liabilities		
Stockholders' equity		
Preferred stock	237	237
Common stock, \$0.30 par value; 1,800,000,000 shares authorized; Issued at June 30, 2012 - 1,017,365,000; December 31, 2011 - 1,013,164,000	305	304
Additional paid-in capital	10,494	10,107
Reinvested earnings	14,975	13,422
Accumulated other comprehensive loss	(8,743)	(8,750)
Common stock held in treasury, at cost (87,041,000 shares at June 30, 2012 and December 31, 2011)	(6,727)	(6,727)
Total DuPont stockholders' equity	10,541	8,593
Noncontrolling interests	104	469
Total equity	10,645	9,062
Total	\$50,031	\$48,492

See Notes to the Consolidated Financial Statements beginning on page 7.





Table of Contents

E. I. du Pont de Nemours and Company  
 Condensed Consolidated Statements of Cash Flows (Unaudited)  
 (Dollars in millions)

	Six Months Ended June 30,	
	2012	2011
Operating activities		
Net income	\$2,688	\$2,673
Adjustments to reconcile net income to cash used for operating activities:		
Depreciation	702	607
Amortization of intangible assets	198	137
Contributions to pension plans	(692)	(198)
Other noncash charges and credits - net	314	624
Change in operating assets and liabilities - net	(4,327)	(4,487)
Cash used for operating activities	(1,117)	(644)
Investing activities		
Purchases of property, plant and equipment	(696)	(741)
Investments in affiliates	(14)	(27)
Payments for businesses - net of cash acquired	—	(6,264)
Proceeds from sales of assets - net of cash sold	166	59
Net decrease in short-term financial instruments	388	2,404
Forward exchange contract settlements	80	(454)
Other investing activities - net	(7)	(13)
Cash used for investing activities	(83)	(5,036)
Financing activities		
Dividends paid to stockholders	(788)	(767)
Net increase in borrowings	2,406	3,823
Repurchase of common stock	(400)	(272)
Proceeds from exercise of stock options	406	768
Payments for noncontrolling interest	(447)	—
Other financing activities - net	27	(22)
Cash provided by financing activities	1,204	3,530
Effect of exchange rate changes on cash	(84)	155
Decrease in cash and cash equivalents	\$(80)	\$(1,995)
Cash and cash equivalents at beginning of period	3,586	4,263
Cash and cash equivalents at end of period	\$3,506	\$2,268

See Notes to the Consolidated Financial Statements beginning on page 7.

Table of Contents

## NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in millions, except per share)

## Note 1. Summary of Significant Accounting Policies

## Interim Financial Statements

The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (GAAP) for interim financial information and the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair statement of the results for interim periods have been included. Results for interim periods should not be considered indicative of results for a full year. These interim Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and Notes thereto contained in the company's Annual Report on Form 10-K for the year ended December 31, 2011, collectively referred to as the "2011 Annual Report". The Consolidated Financial Statements include the accounts of the company and all of its subsidiaries in which a controlling interest is maintained, as well as variable interest entities for which DuPont is the primary beneficiary.

## Note 2. Other Income, Net

	Three Months Ended		Six Months Ended	
	June 30,		June 30,	
	2012	2011	2012	2011
Cozaar <sup>®</sup> /Hyzaar <sup>®</sup> income	\$14	\$79	\$39	\$127
Royalty income	25	35	66	66
Interest income	37	32	60	60
Equity in earnings of affiliates, excluding exchange gains/losses	21	35	31	83
Gain on sale of equity method investment	122	—	122	—
Net gain on sales of other assets	5	33	10	39
Net exchange gains (losses) <sup>1</sup>	28	4	(52)	(139)
Miscellaneous income and expenses, net <sup>2</sup>	25	11	27	18
Total	\$277	\$229	\$303	\$254

The company routinely uses foreign currency exchange contracts to offset its net exposures, by currency, related to the foreign currency-denominated monetary assets and liabilities. The objective of this program is to maintain an approximately balanced position in foreign currencies in order to minimize, on an after-tax basis, the effects of exchange rate changes on net monetary asset positions. The net pre-tax exchange gains and losses are recorded in other income, net and the related tax impact is recorded in provision for income taxes on the interim Consolidated Income Statements.

<sup>2</sup> Miscellaneous income and expenses, net, generally includes interest items, insurance recoveries, litigation settlements and other items.

## Note 3. Provision for Income Taxes

In the second quarter 2012, the company recorded a tax provision of \$449, including \$59 of tax expense primarily associated with the company's policy of hedging the foreign currency-denominated monetary assets and liabilities of its operations.

Year-to-date 2012, the company recorded a tax provision of \$890, including \$23 of tax expense primarily associated with the company's policy of hedging the foreign currency denominated monetary assets and liabilities of its operations.

In the second quarter 2011, the company recorded a tax provision of \$360, including \$7 of tax benefit primarily associated with the company's policy of hedging the foreign currency-denominated monetary assets and liabilities of its operations.

Year-to-date 2011, the company recorded a tax provision of \$618, including \$142 of tax benefit primarily associated with the company's policy of hedging the foreign currency denominated monetary assets and liabilities of its operations.

Each year the company files hundreds of tax returns in the various national, state and local income taxing jurisdictions in which it operates. These tax returns are subject to examination and possible challenge by the taxing authorities. Positions challenged by the taxing authorities may be settled or appealed by the company. As a result, there is an uncertainty in income taxes recognized in the company's financial statements in accordance with accounting for income taxes and accounting for uncertainty in income taxes. It is reasonably possible that changes to the company's global unrecognized tax benefits could be significant, however, due to the uncertainty regarding the timing of completion of audits and possible outcomes, a current estimate of the range of increases or decreases that may occur within the next twelve months cannot be made.

Table of Contents

## NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in millions, except per share)

## Note 4. Earnings Per Share of Common Stock

Set forth below is a reconciliation of the numerator and denominator for basic and diluted earnings per share calculations for the periods indicated:

	Three Months Ended June 30,		Six Months Ended June 30,	
	2012	2011	2012	2011
Numerator:				
Net income attributable to DuPont	\$1,179	\$1,218	\$2,667	\$2,649
Preferred dividends	(2	)(2	)(5	)(5
Net income available to common stockholders	\$1,177	\$1,216	\$2,662	\$2,644
Denominator:				
Weighted-average number of common shares outstanding - Basic	934,057,000	930,798,000	933,982,000	927,860,000
Dilutive effect of the company's employee compensation plans	8,775,000	13,189,000	9,551,000	14,601,000
Weighted-average number of common shares outstanding - Diluted	942,832,000	943,987,000	943,533,000	942,461,000

The following average number of stock options were antidilutive, and therefore, were not included in the diluted earnings per share calculations:

	Three Months Ended June 30,		Six Months Ended June 30,	
	2012	2011	2012	2011
Average number of stock options	12,750,000	—	11,737,000	—

The change in the average number of stock options that were antidilutive in the three and six months ended June 30, 2012 compared to the same periods last year was primarily due to changes in the company's average stock price.

## Note 5. Inventories

	June 30, 2012	December 31, 2011
Finished products	\$3,927	\$4,541
Semifinished products	1,746	2,293
Raw materials, stores and supplies	1,234	1,262
	6,907	8,096
Adjustment of inventories to a last-in, first-out (LIFO) basis	(896	)(901
Total	\$6,011	\$7,195

Table of Contents

## NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in millions, except per share)

## Note 6. Goodwill and Other Intangible Assets

There were no significant changes in goodwill for the six months ended June 30, 2012.

The gross carrying amounts and accumulated amortization of other intangible assets by major class are as follows:

	June 30, 2012			December 31, 2011		
	Gross	Accumulated Amortization	Net	Gross	Accumulated Amortization	Net
Intangible assets subject to amortization (Definite-lived):						
Customer lists	\$1,802	\$(274)	)\$1,528	\$1,841	\$(220)	)\$1,621
Patents	510	(101)	)409	518	(77)	)441
Purchased and licensed technology	1,921	(976)	)945	1,854	(878)	)976
Trademarks	57	(27)	)30	57	(25)	)32
Other <sup>1</sup>	327	(153)	)174	330	(151)	)179
	4,617	(1,531)	)3,086	4,600	(1,351)	)3,249
Intangible assets not subject to amortization(Indefinite-lived):						
In-process research and development	69	—	69	70	—	70
Microbial cell factories <sup>2</sup>	306	—	306	306	—	306
Pioneer germplasm <sup>3</sup>	975	—	975	975	—	975
Trademarks/tradenames	792	—	792	813	—	813
	2,142	—	2,142	2,164	—	2,164
Total	\$6,759	\$(1,531)	)\$5,228	\$6,764	\$(1,351)	)\$5,413

<sup>1</sup> Primarily consists of sales and grower networks, marketing and manufacturing alliances and noncompetition agreements.

<sup>2</sup> Microbial cell factories, derived from natural microbes, are used to sustainably produce enzymes, peptides and chemicals using natural metabolic processes. The company recognized the microbial cell factories as an intangible asset upon the acquisition of Danisco. This intangible asset is expected to contribute to cash flows beyond the foreseeable future and there are no legal, regulatory, contractual, or other factors which limit its useful life.

<sup>3</sup> Pioneer germplasm is the pool of genetic source material and body of knowledge gained from the development and delivery stage of plant breeding. The company recognized germplasm as an intangible asset upon the acquisition of Pioneer. This intangible asset is expected to contribute to cash flows beyond the foreseeable future and there are no legal, regulatory, contractual, or other factors which limit its useful life.

The aggregate pre-tax amortization expense for definite-lived intangible assets was \$92 and \$198 for the three and six months ended June 30, 2012, respectively, and \$70 and \$137 for the three and six months ended June 30, 2011, respectively. The estimated aggregate pre-tax amortization expense for the remainder of 2012 and each of the next five years is approximately \$140, \$332, \$348, \$351, \$308 and \$180.

## Note 7. Commitments and Contingent Liabilities

## Guarantees

## Indemnifications

In connection with acquisitions and divestitures, the company has indemnified respective parties against certain liabilities that may arise in connection with these transactions and business activities prior to the completion of the transaction. The term of these indemnifications, which typically pertain to environmental, tax and product liabilities, is

generally indefinite. In addition, the company indemnifies its duly elected or appointed directors and officers to the fullest extent permitted by Delaware law, against liabilities incurred as a result of their activities for the company, such as adverse judgments relating to litigation matters. If the indemnified party were to incur a liability or have a liability increase as a result of a successful claim, pursuant to the terms of the indemnification, the company would be required to reimburse the indemnified party. The maximum amount of potential future payments is generally unlimited. Although it is reasonably possible that future payments may exceed amounts accrued, due to the nature of indemnified items, it is not possible to make a reasonable estimate of the maximum potential loss or range of loss. No assets are held as collateral and no specific recourse provisions exist. The carrying amounts recorded for all indemnifications as of June 30, 2012 and December 31, 2011 were \$241 and \$105, respectively. The increase in the carrying amount at June 30, 2012 primarily relates to the settlement of the 2008 lawsuit filed by subsidiaries of Koch Industries, Inc. (INVISTA) alleging that certain representations and warranties in the Purchase and Sale Agreement concerning the sale of the majority of the net assets of Textiles and Interiors were breached.

Table of Contents

## NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in millions, except per share)

## Obligations for Equity Affiliates &amp; Others

The company has directly guaranteed various debt obligations under agreements with third parties related to equity affiliates, customers and suppliers. At June 30, 2012 and December 31, 2011, the company had directly guaranteed \$485 and \$563, respectively, of such obligations. These amounts represent the maximum potential amount of future (undiscounted) payments that the company could be required to make under the guarantees. The company would be required to perform on these guarantees in the event of default by the guaranteed party.

The company assesses the payment/performance risk by assigning default rates based on the duration of the guarantees. These default rates are assigned based on the external credit rating of the counterparty or through internal credit analysis and historical default history for counterparties that do not have published credit ratings. For counterparties without an external rating or available credit history, a cumulative average default rate is used.

In certain cases, the company has recourse to assets held as collateral, as well as personal guarantees from customers and suppliers. Assuming liquidation, these assets are estimated to cover approximately 48 percent of the \$287 of guaranteed obligations of customers and suppliers. Set forth below are the company's guaranteed obligations at June 30, 2012:

	Short-Term	Long-Term	Total
Obligations for customers and suppliers <sup>1</sup> :			
Bank borrowings (terms up to 5 years)	\$ 167	\$ 120	\$ 287
Obligations for equity affiliates <sup>2</sup> :			
Bank borrowings (terms up to 1 year)	198	—	198
Total	\$ 365	\$ 120	\$ 485

<sup>1</sup> Existing guarantees for customers and suppliers arose as part of contractual agreements.

<sup>2</sup> Existing guarantees for equity affiliates arose for liquidity needs in normal operations.

## Imprelis®

The company has received claims and been served with multiple lawsuits alleging that the use of Imprelis® herbicide caused damage to certain trees. The lawsuits seeking class action status have been consolidated in federal court in Philadelphia, Pennsylvania. In addition, about 60 individual actions have been filed in state court in various jurisdictions. DuPont is seeking to remove these cases to federal court.

In August 2011, the company suspended sales of Imprelis® and in September began a process to fairly resolve claims associated with the use of Imprelis®. The deadline for property owners to file claims was February 1, 2012, although DuPont continues to receive claims at a declining rate which it expects to consider as part of the claims resolution process. However, the company believes that the number of unasserted claims is limited due to the fact that sales were suspended in August 2011 and the product was last applied during the 2011 spring application season.

The company has established review processes to verify and evaluate damage claims. There are several variables that impact the evaluation process including the number of trees on a property, the species of tree with reported damage, the height of the tree, the extent of damage and the possibility for trees to naturally recover over time. Upon receiving claims, DuPont verifies their accuracy and validity which often requires physical review of the property.

At June 30, 2012, DuPont had recorded charges of \$490 related to the Imprelis® matter, which included charges of \$265 and \$315 recorded during the second quarter and year-to-date 2012, respectively. It is reasonably possible that additional charges could result related to this matter. While there is a high degree of uncertainty, total charges could

range as high as \$575. DuPont has submitted and will continue to submit requests for payment to its insurance carriers for costs associated with this matter in excess of \$100.

#### Litigation

The company is subject to various legal proceedings arising out of the normal course of its business including product liability, intellectual property, commercial, environmental and antitrust lawsuits. It is not possible to predict the outcome of these various proceedings. Except as otherwise noted, management does not anticipate their resolution will have a materially adverse effect on the company's consolidated financial position or liquidity. However, the ultimate liabilities could be significant to results of operations in the period recognized.



Table of Contents

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in millions, except per share)

PFOA

DuPont uses PFOA (collectively, perfluorooctanoic acids and its salts, including the ammonium salt), as a processing aid to manufacture fluoropolymer resins and dispersions at various sites around the world including its Washington Works plant in West Virginia. At June 30, 2012, DuPont has accruals of \$16 related to the PFOA matters discussed below.

The accrual includes charges related to DuPont's obligations under agreements with the U.S. Environmental Protection Agency and voluntary commitments to the New Jersey Department of Environmental Protection. These obligations include surveying, sampling and testing drinking water in and around certain company sites and offering treatment or an alternative supply of drinking water if tests indicate the presence of PFOA in drinking water at or greater than the national Provisional Health Advisory.

Drinking Water Actions

In August 2001, a class action, captioned *Leach v DuPont*, was filed in West Virginia state court alleging that residents living near the Washington Works facility had suffered, or may suffer, deleterious health effects from exposure to PFOA in drinking water.

DuPont and attorneys for the class reached a settlement in 2004 that binds about 80,000 residents. In 2005, DuPont paid the plaintiffs' attorneys' fees and expenses of \$23 and made a payment of \$70, which class counsel designated to fund a community health project. The company is also funding a series of health studies by an independent science panel of experts (the "C8 Science Panel") in the communities exposed to PFOA to evaluate available scientific evidence on whether any probable link exists, as defined in the settlement agreement, between exposure to PFOA and human disease. The company expects the C8 Science Panel to complete these health studies through October 2012 at a total estimated cost of \$33.

In December 2011, the C8 Science Panel concluded that there is a probable link, as defined in the settlement agreement, between exposure to PFOA and pregnancy-induced hypertension, which includes preeclampsia. In April 2012, the C8 Science Panel announced its probable link determinations regarding cancer and adult onset diabetes. The C8 Science Panel found a probable link between exposure to PFOA and two categories of cancer (kidney and testicular). A panel of medical experts will determine an appropriate medical monitoring protocol, if any, as a result of these findings. If a medical monitoring protocol for any of these diseases is defined, DuPont is required to fund a medical monitoring program to pay for such medical testing. Plaintiffs may pursue personal injury claims against DuPont only for those human diseases for which the C8 Science Panel determines a probable link exists once the C8 Science Panel completes its work. In January 2012, the company put \$1 in an escrow account as required by the settlement agreement. The company will reassess its liability based on the medical monitoring panel's determination since costs are not reasonably estimable until a medical monitoring protocol, if any, is identified. The company will continue to reassess its liability based on the C8 Science Panel's future probable link findings, if any, and associated medical monitoring protocols, if any. Under the settlement agreement, the company's total obligation to pay for medical monitoring cannot exceed \$235. In addition, the company must continue to provide water treatment designed to reduce the level of PFOA in water to six area water districts, including the Little Hocking Water Association (LHWA), and private well users.

An Ohio action brought by the LHWA is currently in discovery. In addition to general claims of PFOA contamination of drinking water, the action claims "imminent and substantial endangerment to health and or the environment" under the Resource Conservation and Recovery Act (RCRA). DuPont denies these claims and is defending itself vigorously.

While DuPont believes that it is reasonably possible that it could incur losses related to PFOA matters in addition to those matters discussed above for which it has established accruals, a range of such losses, if any, cannot be reasonably estimated at this time.

#### Environmental

The company is also subject to contingencies pursuant to environmental laws and regulations that in the future may require the company to take further action to correct the effects on the environment of prior disposal practices or releases of chemical or petroleum substances by the company or other parties. The company accrues for environmental remediation activities consistent with the policy as described in the company's 2011 Annual Report in Note 1, "Summary of Significant Accounting Policies." Much of this liability results from the Comprehensive Environmental Response, Compensation and Liability Act (CERCLA, often referred to as Superfund), RCRA and similar state and global laws. These laws require the company to undertake certain investigative, remediation and restoration activities at sites where the company conducts or once conducted operations or at sites where company-generated waste was disposed. The accrual also includes estimated costs related to a number of sites identified by the company for which it is probable that environmental remediation will be required, but which are not currently the subject of enforcement activities.

Remediation activities vary substantially in duration and cost from site to site. These activities, and their associated costs, depend on the mix of unique site characteristics, evolving remediation technologies, diverse regulatory agencies and enforcement policies,

Table of Contents

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in millions, except per share)

as well as the presence or absence of potentially responsible parties. At June 30, 2012, the Condensed Consolidated Balance Sheet included a liability of \$430, relating to these matters and, in management's opinion, is appropriate based on existing facts and circumstances. The average time frame, over which the accrued or presently unrecognized amounts may be paid, based on past history, is estimated to be 15-20 years. Considerable uncertainty exists with respect to these costs and, under adverse changes in circumstances, potential liability may range up to three times the amount accrued as of June 30, 2012.

Other

The company has various purchase commitments incident to the ordinary conduct of business. In the aggregate, such commitments are not at prices in excess of current market.

Note 8. Stockholders' Equity

Share Repurchase Program

During the first quarter 2012, the company entered into an agreement with a financial institution in which the company paid \$400 for the purchase of shares of common stock which were received in the second quarter 2012. As a result, during the second quarter 2012, the company purchased and retired 7.8 million shares in connection with this agreement. These purchases completed the 2001 \$2,000 share buyback plan and began purchases under the 2011 \$2,000 share buyback plan. Under the completed 2001 plan, the company purchased a total of 42.0 million shares. Under the 2011 plan, the company has purchased 5.5 million shares at a total cost of \$284 as of June 30, 2012. There is no required completion date for the purchases under the 2011 plan.

During the three months ended June 30, 2011, there were no purchases of stock under the 2001 plan. During the six months ended June 30, 2011, the company purchased and retired 5.0 million shares at a total cost of \$272 under this plan.

Noncontrolling Interest

In May 2012, the company completed the acquisition of the remaining 28 percent interest in the Solae, LLC joint venture from Bunge Limited for \$447. As the purchase of the remaining interest did not result in a change of control, the difference between the carrying value of the noncontrolling interest of \$362 and the consideration paid, net of taxes of \$74, was recorded as an \$11 reduction to additional paid-in capital.

Table of Contents

## NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in millions, except per share)

## Other Comprehensive Income

A summary of the changes in other comprehensive income for the three and six months ended June 30, 2012 and 2011 is provided as follows:

	Three Months Ended June 30, 2012			Three Months Ended June 30, 2011			
	Pre-Tax	Tax	After-Tax	Pre-Tax	Tax	After-Tax	
Cumulative translation adjustment	\$(412	)\$—	\$(412	)\$73	\$—	\$73	
Net revaluation and clearance of cash flow hedges to earnings:							
Additions and revaluations of derivatives designated as cash flow hedges	38	(15	)23	(5	)2	(3	)
Clearance of hedge results to earnings	(23	)10	(13	)25	(9	)16	
Net revaluation and clearance of cash flow hedges to earnings	15	(5	)10	20	(7	)13	
Pension benefit plans:							
Net gain (loss)	4	7	11	(3	)1	(2	)
Prior service cost	—	(1	)1	(2	)—	(2	)
Amortization of prior service cost	3	(1	)2	4	(1	)3	
Amortization of loss	220	(77	)143	153	(53	)100	
Pension benefit plans, net	227	(72	)155	152	(53	)99	
Other benefit plans:							
Amortization of prior service benefit	(30	)9	(21	)31	)11	(20	)
Amortization of loss	22	(7	)15	15	(5	)10	
Other benefit plans, net	(8	)2	(6	)16	)6	(10	)
Net unrealized gain (loss) on securities:							
Unrealized loss on securities arising during the period	(1	)—	(1	)1	)—	(1	)
Reclassification of loss realized in net income	2	(1	)1	—	—	—	
Net unrealized gain (loss) on securities	1	(1	)—	(1	)—	(1	)
Other comprehensive (loss) income	\$(177	)\$(76	)\$(253	)\$228	\$(54	)\$174	

Table of Contents

## NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in millions, except per share)

	Six Months Ended June 30, 2012			Six Months Ended June 30, 2011			
	Pre-Tax	Tax	After-Tax	Pre-Tax	Tax	After-Tax	
Cumulative translation adjustment	\$(242	)\$—	\$ (242	)\$117	\$—	\$ 117	
Net revaluation and clearance of cash flow hedges to earnings:							
Additions and revaluations of derivatives designated as cash flow hedges	36	(15	)21	3	(1	)2	
Clearance of hedge results to earnings	(55	)23	(32	)52	(20	)32	
Net revaluation and clearance of cash flow hedges to earnings	(19	)8	(11	)55	(21	)34	
Pension benefit plans:							
Net loss	(19	)10	(9	)3	)1	(2	)
Prior service cost	22	(8	)14	(2	)—	(2	)
Amortization of prior service cost	7	(2	)5	8	(2	)6	
Amortization of loss	439	(152	)287	306	(106	)200	
Pension benefit plans, net	449	(152	)297	309	(107	)202	
Other benefit plans:							
Amortization of prior service benefit	(60	)20	(40	)61	)22	(39	)
Amortization of loss	44	(15	)29	30	(10	)20	
Other benefit plans, net	(16	)5	(11	)31	)12	(19	)
Net unrealized gain on securities:							
Unrealized gain on securities arising during the period	—	—	—	—	—	—	
Reclassification of loss realized in net income	2	(1	)1	—	—	—	
Unrealized gain on securities	2	(1	)1	—	—	—	
Other comprehensive income	\$174	\$(140	)\$34	\$450	\$(116	)\$334	

## Note 9. Financial Instruments

## Debt

The estimated fair value of the company's total debt including interest rate financial instruments was determined using level 2 inputs within the fair value hierarchy, as described in the company's 2011 Annual Report in Note 1, "Summary of Significant Accounting Policies." Based on quoted market prices for the same or similar issues or on current rates offered to the company for debt of the same remaining maturities, the fair value of the company's debt was approximately \$16,313 and \$13,880 as of June 30, 2012 and December 31, 2011, respectively.

## Cash Equivalents

The estimated fair value of the company's cash equivalents was determined using level 2 inputs. Based on current interest rates for similar investments with comparable credit risk and time to maturity, the fair value of the company's cash equivalents approximates its stated value of \$1,628 and \$1,932 as of June 30, 2012 and December 31, 2011, respectively.

## Derivative Instruments

## Objectives and Strategies for Holding Derivative Instruments

In the ordinary course of business, the company enters into contractual arrangements (derivatives) to reduce its exposure to foreign currency, interest rate and commodity price risks. The company has established a variety of derivative programs to be utilized for financial risk management. These programs reflect varying levels of exposure

coverage and time horizons based on an assessment of risk.

Derivative programs have procedures and controls and are approved by the Corporate Financial Risk Management Committee, consistent with the company's financial risk management policies and guidelines. Derivative instruments used are forwards, options, futures and swaps. The company has not designated any nonderivatives as hedging instruments.

The company's financial risk management procedures also address counterparty credit approval, limits and routine exposure monitoring and reporting. The counterparties to these contractual arrangements are major financial institutions and major

Table of Contents

## NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in millions, except per share)

commodity exchanges. The company is exposed to credit loss in the event of nonperformance by these counterparties. The company anticipates performance by counterparties to these contracts and therefore no material loss is expected. Market and counterparty credit risks associated with these instruments are regularly reported to management.

The notional amounts of the company's derivative instruments were as follows:

	June 30, 2012	December 31, 2011
Derivatives designated as hedging instruments:		
Interest rate swaps	\$1,000	\$1,000
Foreign currency contracts	1,547	2,032
Commodity contracts	90	553
Derivatives not designated as hedging instruments:		
Foreign currency contracts	8,040	6,444
Commodity contracts	95	437

**Foreign Currency Risk**

The company's objective in managing exposure to foreign currency fluctuations is to reduce earnings and cash flow volatility associated with foreign currency rate changes. Accordingly, the company enters into various contracts that change in value as foreign exchange rates change to protect the value of its existing foreign currency-denominated assets, liabilities, commitments and cash flows.

The company routinely uses forward exchange contracts to offset its net exposures, by currency, related to the foreign currency-denominated monetary assets and liabilities of its operations. The primary business objective of this hedging program is to maintain an approximately balanced position in foreign currencies so that exchange gains and losses resulting from exchange rate changes, net of related tax effects, are minimized. The company also uses foreign currency exchange contracts to offset a portion of the company's exposure to certain foreign currency-denominated revenues so that gains and losses on these contracts offset changes in the USD value of the related foreign currency-denominated revenues. The objective of the hedge program is to reduce earnings and cash flow volatility related to changes in foreign currency exchange rates.

**Interest Rate Risk**

The company uses interest rate swaps to manage the interest rate mix of the total debt portfolio and related overall cost of borrowing.

Interest rate swaps involve the exchange of fixed for floating rate interest payments to effectively convert fixed rate debt into floating rate debt based on USD LIBOR. Interest rate swaps allow the company to achieve a target range of floating rate debt.

**Commodity Price Risk**

Commodity price risk management programs serve to reduce exposure to price fluctuations on purchases of inventory such as copper, corn, soybeans, soybean meal and natural gas. The company enters into over-the-counter and exchange-traded derivative commodity instruments to hedge the commodity price risk associated with energy feedstock and agricultural commodity exposures.

**Fair Value Hedges****Interest Rate Swaps**

At June 30, 2012, the company maintained a number of interest rate swaps, which were implemented at the time debt instruments were issued. All interest rate swaps qualify for the shortcut method of hedge accounting, thus there is no

ineffectiveness related to these hedges.

#### Cash Flow Hedges

##### Foreign Currency Contracts

The company uses foreign currency exchange instruments such as forwards and options to offset a portion of the company's exposure to certain foreign currency-denominated revenues so that gains and losses on these contracts offset changes in the USD value of the related foreign currency-denominated revenues.

##### Commodity Contracts

The company enters into over-the-counter and exchange-traded derivative commodity instruments, including options, futures and swaps, to hedge the commodity price risk associated with energy feedstock and agriculture commodity exposures.



Table of Contents

## NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in millions, except per share)

While each risk management program has a different time maturity period, most programs currently do not extend beyond the next two-year period. Cash flow hedge results are reclassified into earnings during the same period in which the related exposure impacts earnings. Reclassifications are made sooner if it appears that a forecasted transaction will not materialize. The following table summarizes the after-tax effect of cash flow hedges on accumulated other comprehensive income (loss) for the three and six months ended June 30, 2012 and 2011:

	Three Months Ended		Six Months Ended	
	June 30,		June 30,	
	2012	2011	2012	2011
Beginning balance	\$19	\$(9)	)\$41	\$(31)
Net revaluation and clearance of cash flow hedges to earnings	10	15	(12)	)37
Ending balance	\$29	\$6	\$29	\$6

At June 30, 2012, the after-tax amount expected to be reclassified from accumulated other comprehensive income (loss) into earnings over the next 12 months is \$28.

## Derivatives not Designated in Hedging Relationships

## Foreign Currency Contracts

The company routinely uses forward exchange contracts to reduce its net exposure, by currency, related to foreign currency-denominated monetary assets and liabilities of its operations so that exchange gains and losses resulting from exchange rate changes are minimized. The netting of such exposures precludes the use of hedge accounting; however, the required revaluation of the forward contracts and the associated foreign currency-denominated monetary assets and liabilities intends to achieve a minimal earnings impact, after taxes. Additionally, the company has cross-currency swaps to hedge foreign currency fluctuations on long-term intercompany loans.

## Commodity Contracts

The company utilizes options, futures and swaps that are not designated as hedging instruments to reduce exposure to commodity price fluctuations on purchases of inventory such as corn, soybeans and soybean meal.

Table of Contents

## NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in millions, except per share)

## Fair Values of Derivative Instruments

The table below presents the fair values of the company's derivative assets and liabilities within the fair value hierarchy, as described in the company's 2011 Annual Report in Note 1, "Summary of Significant Accounting Policies."

	Balance Sheet Location	Fair Value Using Level 2 Inputs	
		June 30, 2012	December 31, 2011
Asset derivatives:			
Derivatives designated as hedging instruments:			
Interest rate swaps	Other assets	\$62	\$66
Foreign currency contracts	Accounts and notes receivable, net	35	44
		97	110
Derivatives not designated as hedging instruments:			
Foreign currency contracts	Accounts and notes receivable, net	102	100
Foreign currency contracts	Other assets	83	43
		185	143
Total asset derivatives		\$282	\$253
Liability derivatives:			
Derivatives designated as hedging instruments:			
Foreign currency contracts	Other accrued liabilities	\$1	\$12
Commodity contracts	Other accrued liabilities	1	1
		2	13
Derivatives not designated as hedging instruments:			
Foreign currency contracts	Other accrued liabilities	32	21
Commodity contracts	Other accrued liabilities	2	2
		34	23
Total liability derivatives		\$36	\$36

Table of Contents

## NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in millions, except per share)

## Effect of Derivative Instruments

Three Months Ended June 30,	Amount of Gain (Loss) Recognized in OCI <sup>1</sup> (Effective Portion)		Amount of Gain (Loss) Recognized in Income <sup>2</sup>		Income Statement Classification
	2012	2011	2012	2011	
Derivatives designated as hedging instruments:					
Fair value hedges:					
Interest rate swaps	\$—	\$—	\$(1	)\$20	Interest expense <sup>3</sup>
Cash flow hedges:					
Foreign currency contracts	27	1	4	(7	) Net sales
Commodity contracts	12	(4	)19	(18	) COGS <sup>4</sup>
	39	(3	)22	(5	)
Derivatives not designated as hedging instruments:					
Foreign currency contracts	—	—	238	(51	) Other income, net <sup>5</sup>
Commodity contracts	—	—	(3	)10	COGS <sup>4</sup>
Interest rate swaps	—	—	—	(1	) COGS <sup>4</sup>
	—	—	235	(42	)
Total derivatives	\$39	\$(3	)\$257	\$(47	)
Six Months Ended June 30,	Amount of Gain (Loss) Recognized in OCI <sup>1</sup> (Effective Portion)		Amount of Gain (Loss) Recognized in Income <sup>2</sup>		Income Statement Classification
2012	2011	2012	2011		
Derivatives designated as hedging instruments:					
Fair value hedges:					
Interest rate swaps	\$—	\$—	\$(4	)\$9	Interest expense <sup>3</sup>
Cash flow hedges:					
Foreign currency contracts	17	(20	)7	(12	) Net sales
Commodity contracts	18	26	48	(40	) COGS <sup>4</sup>
	35	6	51	(43	)
Derivatives not designated as hedging instruments:					
Foreign currency contracts	—	—	110	(424	) Other income, net <sup>5</sup>
Commodity contracts	—	—	(14	)11	COGS <sup>4</sup>
Interest rate swaps	—	—	—	(1	) COGS <sup>4</sup>
	—	—	96	(414	)
Total derivatives	\$35	\$6	\$147	\$(457	)

<sup>1</sup> OCI is defined as other comprehensive income (loss).<sup>2</sup> For cash flow hedges, this represents the effective portion of the gain (loss) reclassified from accumulated OCI into income during the period. For the three and six months ended June 30, 2012 and 2011, there was no material ineffectiveness with regard to the company's cash flow hedges.

3 Gain (loss) recognized in income of derivative is offset to \$0 by gain (loss) recognized in income of the hedged  
item.

4 COGS is defined as costs of goods sold and other operating charges.

Gain (loss) recognized in other income, net, was partially offset by the related gain (loss) on the foreign  
5 currency-denominated monetary assets and liabilities of the company's operations, which were \$(210) and \$55 for  
the three months ended June 30, 2012 and 2011, respectively, and \$(162) and \$285 for the six months ended  
June 30, 2012 and 2011, respectively.

Table of Contents

## NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in millions, except per share)

## Note 10. Long-Term Employee Benefits

The following sets forth the components of the company's net periodic benefit cost for pensions:

	Three Months Ended		Six Months Ended	
	June 30,		June 30,	
	2012	2011	2012	2011
Service cost	\$66	\$61	\$134	\$120
Interest cost	295	314	592	624
Expected return on plan assets	(379)	(369)	(760)	(734)
Amortization of unrecognized loss	220	153	439	306
Amortization of prior service cost	3	4	7	8
Net periodic benefit cost	\$205	\$163	\$412	\$324

The following sets forth the components of the company's net periodic benefit cost for other long-term employee benefits:

	Three Months Ended		Six Months Ended	
	June 30,		June 30,	
	2012	2011	2012	2011
Service cost	\$10	\$9	\$19	\$17
Interest cost	48	53	96	106
Amortization of unrecognized loss	22	15	44	30
Amortization of prior service benefit	(30)	(31)	(60)	(61)
Net periodic benefit cost	\$50	\$46	\$99	\$92

## Note 11. Segment Information

Segment sales include transfers to another business segment. Products are transferred between segments on a basis intended to reflect, as nearly as practicable, the market value of the products. Segment pre-tax operating income (loss) (PTOI) is defined as income (loss) before income taxes excluding exchange gains (losses), corporate expenses and interest.

Three Months Ended June 30,	Agriculture	Electronics & Communications	Industrial & Biosciences	Nutrition & Health	Performance Chemicals	Performance Coatings	Performance Materials	Safety & Protection	Pharmaceuticals	Other	Total
2012											
Segment sales	\$ 3,388	\$ 795	\$ 300	\$ 885	\$ 1,968	\$ 1,089	\$ 1,699	\$ 986	\$ —	\$ 1	\$ 11,111
Less: Transfers	2	5	2	—	69	—	24	3	—	—	105
Net sales	3,386	790	298	885	1,899	1,089	1,675	983	—	1	11,006
PTOI	661	<sup>2</sup> 197	<sup>3</sup> 44	112	538	92	317	127	16	(206) <sup>4</sup>	1,898
2011											
Segment sales	\$ 2,997	\$ 891	\$ 123	\$ 486	\$ 1,995	\$ 1,105	\$ 1,745	\$ 1,025	\$ —	\$ 1	\$ 10,368
Less: Transfers	—	5	1	—	69	—	26	3	—	—	104
Net sales	2,997	886	122	486	1,926	1,105	1,719	1,022	—	1	10,264
PTOI	826	103	(7)	<sup>5</sup> 5	<sup>5</sup> 503	73	254	143	80	(37)	1,943



Table of Contents

## NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in millions, except per share)

Six Months Ended June 30, 2012	Agriculture	Electronics & Communications	Industrial Biosciences	Nutrition & Health	Performance Chemicals	Performance Coatings	Performance Materials	Safety & Protection	Pharmaceuticals	Other	Total
Segment sales	\$ 7,468	\$ 1,472	\$ 588	\$ 1,693	\$ 3,868	\$ 2,139	\$ 3,299	\$ 1,927	\$ —	\$ 2	\$ 22,456
Less: Transfers	4	9	5	—	146	—	50	6	—	—	220
Net sales	7,464	1,463	583	1,693	3,722	2,139	3,249	1,921	—	2	22,236
PTOI	1,925	<sup>2</sup> 230	<sup>3</sup> 85	195	1,050	179	557	227	43	(266) <sup>4</sup>	4,225
2011											
Segment sales	\$ 6,501	\$ 1,702	\$ 123	\$ 810	\$ 3,792	\$ 2,098	\$ 3,452	\$ 1,990	\$ —	\$ 37	\$ 20,505
Less: Transfers	—	10	1	—	136	—	54	6	—	—	207
Net sales	6,501	1,692	122	810	3,656	2,098	3,398	1,984	—	37	20,298
PTOI	1,937	214	(7)	<sup>5</sup> 30	<sup>5</sup> 897	138	542	288	130	(101)	4,068

As of June 30, 2012, Agriculture net assets were \$8,221, an increase of \$3,456 from \$4,765 at December 31, 2011.

<sup>1</sup> The increase was primarily due to higher trade receivables due to normal seasonality in the sales and cash collections cycle.

Included charges of \$(265) and \$(315) during the three and six months ended June 30, 2012, respectively, recorded in cost of goods sold and other operating charges associated with the company's process to fairly resolve claims associated with the use of Imprelis®. See Note 7 for additional information.

<sup>3</sup> Included a \$122 gain recorded in other income, net related to the sale of the company's interest in an equity method investment.

<sup>4</sup> Included a \$(137) charge recorded in cost of goods sold and other operating charges primarily related to the company's settlement of litigation with INVISTA. See Note 7 for additional information.

<sup>5</sup> Included a \$(50) charge for transaction related costs and the fair value step-up of inventories that were acquired as part of the Danisco acquisition in 2011, which impacted the segments as follows: Industrial Biosciences - \$(17) and Nutrition & Health - \$(33).

## Reconciliation to Consolidated Income Statements

	Three Months Ended		Six Months Ended	
	June 30, 2012	2011	June 30, 2012	2011
Total segment PTOI	\$1,898	\$1,943	\$4,225	\$4,068
Net exchange gains (losses), including affiliates	28	4	(52)	(139)
Corporate expenses and net interest	(289)	(358)	(595)	(638)
Income before income taxes	\$1,637	\$1,589	\$3,578	\$3,291

Table of Contents

Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Cautionary Statements About Forward-Looking Statements

This report contains forward-looking statements which may be identified by their use of words like "plans," "expects," "will," "anticipates," "believes," "intends," "projects," "estimates" or other words of similar meaning. All statements that address expectations or projections about the future, including statements about the company's strategy for growth, product development, regulatory approval, market position, anticipated benefits of recent acquisitions, outcome of contingencies, such as litigation and environmental matters, expenditures and financial results, are forward-looking statements.

Forward-looking statements are based on certain assumptions and expectations of future events which may not be accurate or realized. Forward-looking statements also involve risks and uncertainties, many of which are beyond the company's control. Some of the important factors that could cause the company's actual results to differ materially from those projected in any such forward-looking statements are:

- Fluctuations in energy and raw material prices;
- Failure to develop and market new products and optimally manage product life cycles;
- Outcome of significant litigation and environmental matters, including those related to divested businesses;
- Failure to appropriately manage process safety and product stewardship issues;
- Effect of changes in tax, environmental and other laws and regulations or political conditions in the United States of America (U.S.) and other countries in which the company operates;
- Conditions in the global economy and global capital markets, including economic factors, such as inflation, deflation and fluctuations in currency exchange rates, interest rates and commodity prices, as well as regulatory requirements;
- Impact of business disruptions, including supply disruptions, and security threats, regardless of cause, including acts of sabotage, cyber-attacks, terrorism or war, weather events and natural disasters;
- Inability to protect and enforce the company's intellectual property rights; and
- Successful integration of acquired businesses and completion of divestitures of underperforming or non-strategic assets or businesses.

For additional information on these and other risks and factors that could affect our forward-looking statements, see the company's Risk Factors set forth under Part I, Item 1A of the company's 2011 Annual Report.

Results of Operations

Overview

The company continued to execute its strategy for growth by applying its science and technology to address three challenges driven by global population growth: feeding the world, reducing our dependence on fossil fuels and keeping people and the environment safe. The following are highlights from the results of operations for the three and six months ended June 30, 2012:

• Second quarter and year-to-date 2012 earnings were \$1.25 and \$2.82 per share, respectively, versus \$1.29 and \$2.80 per share in the same periods last year.

• Sales of \$11.0 billion for the second quarter 2012 were up 7 percent including 6 percent higher local prices and a 5 percent net sales increase from portfolio changes. Volume was 1 percent lower compared to the same period last year, but increased sequentially from the first quarter to the seasonally stronger second quarter. Sales in developing markets<sup>1</sup> grew 11 percent, led by growth in Agriculture and the benefit of prior-year acquisitions in Nutrition & Health and Industrial Biosciences. Year-to-date sales of \$22.2 billion were up \$1.9 billion or 10 percent.

• Segment pre-tax operating income for the second quarter 2012 was \$1,898 million versus \$1,943 million for the same period last year. Year-to-date segment pre-tax operating income was \$4,225 million, up 4 percent compared to the



same period last year.

DuPont continues to achieve fixed cost, working capital and variable cost productivity through disciplined business processes called DuPont Integrated Business Management and DuPont Production Systems. The company is ahead of plan versus its full-year 2012 productivity targets of \$300 million for both fixed costs and working capital, achieving year-to-date improvements of approximately \$190 million for fixed costs.

---

<sup>1</sup> Developing markets include China, India and countries located in Latin America, Eastern and Central Europe, Middle East, Africa and Southeast Asia.

21

---

Table of Contents

## Net Sales

Net sales for the second quarter 2012 were \$11.0 billion versus \$10.3 billion in the prior year, an increase of 7 percent, reflecting 6 percent higher local prices and a 5 percent net increase from portfolio changes, principally the Danisco acquisition, partly offset by a 3 percent reduction from currency impact and 1 percent lower volume. The decline in total company volume reflects higher volumes for Agriculture, Nutrition & Health, Performance Materials and Industrial Biosciences, more than offset by lower combined volume for the other segments. Sales in developing markets totaling \$3.4 billion increased 11 percent from 2011 including the benefit from portfolio changes. The percentage of total company sales in these markets increased to 30 percent from 29 percent in the prior year.

The table below shows a regional breakdown of net sales based on location of customers and percentage variances from the prior year:

	Three Months Ended June 30, 2012		Percent Change Due to:			
	Net Sales (\$ Billions)	Percent Change vs. 2011	Local Price	Currency Effect	Volume	Portfolio
Worldwide	\$11.0	7	6	(3	)1	)5
U.S. & Canada	5.0	12	8	—	2	2
Europe, Middle East & Africa (EMEA)	2.5	(2	)5	(7	)8	)8
Asia Pacific	2.4	5	1	(1	)1	)6
Latin America	1.1	14	9	(5	)4	6

Net sales for the six months ended June 30, 2012 were \$22.2 billion versus \$20.3 billion in the prior year, an increase of 10 percent, reflecting a 6 percent net increase from portfolio changes, principally the Danisco acquisition, and an 8 percent increase in local prices, partly offset by 2 percent lower volume and a 2 percent sales reduction from currency impact. The decline in total company volume reflects higher Agriculture global volume more than offset by lower volume for the other segments combined, primarily related to lower demand in the EMEA and Asia Pacific regions. Sales in developing markets totaling \$6.8 billion improved 13 percent from 2011 including the benefit from portfolio changes. The percentage of total company sales in these markets increased to 31 percent from 30 percent in the prior year.

	Six Months Ended June 30, 2012		Percent Change Due to:			
	Net Sales (\$ Billions)	Percent Change vs. 2011	Local Price	Currency Effect	Volume	Portfolio
Worldwide	\$22.2	10	8	(2	)2	)6
U.S. & Canada	9.8	13	9	—	1	3
EMEA	5.7	7	7	(5	)5	)10
Asia Pacific	4.4	3	3	—	(7	)7
Latin America	2.3	19	13	(4	)4	6

## Other Income, Net

Other income, net, totaled \$277 million for the second quarter 2012, an increase of \$48 million compared to \$229 million in the prior year. The increase was due primarily to a \$122 million gain recorded during the second quarter 2012 related to the sale of the company's interest in an equity method investment, partially offset by a decrease in Cozaar®/Hyzaar® income of \$65 million.

For the six months ended June 30, 2012, other income, net was \$303 million compared to \$254 million last year, an increase of \$49 million. The increase was due primarily to the \$122 million gain as described above, partially offset by a decrease in Cozaar<sup>®</sup>/Hyzaar<sup>®</sup> income of \$88 million.

Additional information related to the company's other income, net, is included in Note 2 to the interim Consolidated Financial Statements.

## Table of Contents

### Cost of Goods Sold and Other Operating Charges (COGS)

COGS totaled \$7.8 billion in the second quarter 2012 versus \$7.2 billion in the prior year, an increase of 9 percent. COGS as a percent of net sales increased 1 percentage point to 71 percent, principally due to charges for Imprelis® herbicide claims and the company's settlement of litigation with INVISTA. See Note 7 to the interim Consolidated Financial Statements for more information related to these matters. Higher local selling prices and productivity improvements more than offset a 1 percent increase in raw material, energy and freight costs.

COGS for the six months ended June 30, 2012 was \$15.3 billion, an increase of 9 percent versus \$14.0 billion in the prior year. COGS as a percent of net sales was unchanged at 69 percent as a 4 percent increase in raw material, energy and freight costs, and the charges described above, were offset by higher local selling prices and productivity improvements.

### Selling, General and Administrative Expenses (SG&A)

SG&A totaled \$1.2 billion for the second quarter 2012 versus \$1.1 billion in the prior year. Year-to-date SG&A totaled \$2.4 billion versus \$2.2 billion in 2011. The increase for the three and six months ended June 30, 2012 was due to additional selling expense of acquired companies and increased global commissions and selling and marketing investments primarily in the Agriculture segment. SG&A was approximately 11 percent of net sales for the three and six months ended June 30, 2012 and 2011.

### Research and Development Expense (R&D)

R&D totaled \$528 million and \$462 million for the second quarter 2012 and 2011, respectively. For the six months ended June 30, 2012, R&D was \$1.0 billion versus \$861 million last year. The increase for the three and six months ended June 30, 2012 in R&D was primarily due to the addition of R&D from acquired companies and continued growth investments in the Agriculture segment, primarily related to spending for development of new products. R&D was approximately 5 percent of net sales for the second quarter 2012 and 2011, respectively. R&D was approximately 5 percent and 4 percent of net sales for the six months ended June 30, 2012 and 2011, respectively.

### Interest Expense

Interest expense totaled \$117 million in the second quarter 2012, essentially flat compared to \$115 million in 2011. For the six month period ended June 30, 2012, interest expense was \$231 million versus \$215 million last year. The increase for the six months ended June 30, 2012 was primarily due to higher average debt, partially offset by lower interest rates.

### Provision for Income Taxes

The company's effective tax rate for the second quarter 2012 was 27.4 percent as compared to 22.7 percent in 2011. The company's effective tax rate for year-to-date 2012 was 24.9 percent as compared to 18.8 percent in 2011. The higher effective tax rate in second quarter and year-to-date 2012 versus 2011 principally relates to geographic mix of earnings.

See Note 3 to the interim Consolidated Financial Statements for additional information.

### Net Income Attributable to DuPont

Net income attributable to DuPont for the second quarter and year-to-date 2012 was \$1.2 billion and \$2.7 billion, respectively, essentially unchanged from the same periods last year for the reasons noted above.

### Segment Reviews

Summarized below are comments on individual segment sales and pre-tax operating income (loss) (PTOI) for the three and six month periods ended June 30, 2012 compared with the same periods in 2011. Segment sales include transfers to another business segment. Products are transferred between segments on a basis intended to reflect, as

nearly as practicable, the market value of the products. Segment PTOI is defined as income (loss) before income taxes excluding exchange gains (losses), corporate expenses and interest. All references to selling prices are on a U.S. dollar (USD) basis, including the impact of currency. A reconciliation of segment sales to consolidated net sales and segment PTOI to income before income taxes for the three and six month periods ended June 30, 2012 and 2011 is included in Note 11 to the interim Consolidated Financial Statements.

Table of Contents

The following table summarizes second quarter and year-to-date 2012 segment sales and related variances versus prior year:

	Three Months Ended		Percentage Change Due to:		
	June 30, 2012	Percent	Selling	Volume	Portfolio
Segment	Sales	Change vs.	Price		and Other
	(\$ Billions)	2011			
Agriculture	\$3.4	13	7	6	—
Electronics & Communications	0.8	(11)	) (5	) (6	) —
Industrial Biosciences	0.3	144	—	10	134
Nutrition & Health	0.9	82	—	5	77
Performance Chemicals	2.0	(1)	) 9	(10	) —
Performance Coatings	1.1	(1)	) 1	(2	) —
Performance Materials	1.7	(3)	) (1	) 1	(3 )
Safety & Protection	1.0	(4)	) 1	(5	) —

	Six Months Ended		Percentage Change Due to:		
	June 30, 2012	Percent	Selling	Volume	Portfolio
Segment	Sales	Change vs.	Price		and Other
	(\$ Billions)	2011			
Agriculture	\$7.5	15	7	8	—
Electronics & Communications	1.5	(14)	) (2	) (12	) —
Industrial Biosciences	0.6	378	—	10	368
Nutrition & Health	1.7	109	—	1	108
Performance Chemicals	3.9	2	13	(11	) —
Performance Coatings	2.1	2	3	(1	) —
Performance Materials	3.3	(4)	) 2	(4	) (2 )
Safety & Protection	1.9	(3)	) 2	(5	) —

Agriculture - Sales of \$3.4 billion were up \$0.4 billion, or 13 percent, with 7 percent price and 6 percent volume gains. Pioneer seed delivered 12 percent sales growth on agriculture macros and strong business performance in North American corn and soybean sales, partially offset by the expected decline in Europe corn sales resulting from the strong, early start to the European season which favored the first quarter 2012. Crop Protection sales growth of 15 percent was underpinned by strong demand across all product lines. PTOI of \$661 million decreased \$165 million as strong sales performance was more than offset by a \$265 million charge related to Imprelis® claims, input cost increases in seeds, unfavorable currency impact and higher investments in Right Product Right Acre commercial and R&D activities. See Note 7 to the interim Consolidated Financial Statements for more information related to the Imprelis® matter.

Year-to-date sales of \$7.5 billion were up \$1.0 billion, or 15 percent, with 8 percent volume and 7 percent price gains. Pioneer seed sales growth of 16 percent reflects strong northern hemisphere and Brazil Safrinha performance with global price and volume gains on new product penetration. Crop Protection sales growth of 11 percent reflects continued strong demand in all product lines with standout performance in insect control products. PTOI of \$1.9 billion was essentially flat as higher volume and price were offset by a \$315 million charge related to Imprelis® claims, input cost increases in seeds, unfavorable currency impact and higher spending for growth investments.

Electronics & Communications - Sales of \$795 million were down 11 percent on 6 percent lower volume and 5 percent lower selling prices, primarily pass-through of lower metals prices. Sales reflect continued soft demand for

photovoltaic materials, though up sequentially from first quarter 2012. Volume decline in photovoltaics was partially offset by increased demand for smart phones and tablets. PTOI of \$197 million increased \$94 million from a \$122 million gain related to the sale of the company's interest in an equity method investment, partially offset by lower volume and plant utilization. Additionally, 2011 PTOI included a \$20 million reduction due to extreme volatility in metals prices.

Table of Contents

Year-to-date sales of \$1.5 billion were down 14 percent on 12 percent lower volume and 2 percent lower selling prices, primarily pass-through of lower metals prices. Sales reflect continued soft demand in photovoltaic materials, partially offset by increased demand for smart phones and tablets. PTOI of \$230 million increased \$16 million from the \$122 million gain as described above, partially offset by lower volume and plant utilization. Additionally, 2011 PTOI included the \$20 million reduction from metals prices noted above.

Industrial Biosciences - Sales of \$300 million were up \$177 million, primarily due to two months acquisition benefit from the Danisco enzyme business. Sales of Sorona<sup>®</sup> renewably sourced polymer for apparel and carpeting accounted for much of the volume increase. PTOI of \$44 million was up \$51 million benefiting from the acquisition, realization of cost synergies and the absence of a \$17 million charge recorded in the prior year for transaction related costs and the fair value step-up of inventories that were acquired. 2012 PTOI includes \$5 million of amortization expense associated with the fair value step-up of acquired intangible assets.

Year-to-date sales of \$588 million and PTOI of \$85 million primarily reflect the Danisco acquisition. 2012 PTOI includes \$10 million of amortization expense associated with the fair value step-up of acquired intangible assets and excludes a \$17 million charge recorded in the prior year as described above.

Nutrition & Health - Sales of \$885 million were up \$399 million, or 82 percent, primarily reflecting two months acquisition benefit from the Danisco specialty food ingredients business. Higher volume reflects continued strong demand in Solae specialty soy products. PTOI of \$112 million was up \$107 million benefiting from the acquisition, realization of cost synergies, favorable product mix in Solae and the absence of a \$33 million charge recorded in the prior year for transaction related costs and the fair value step-up of inventories that were acquired. 2012 PTOI includes \$20 million of amortization expense associated with the fair value step-up of acquired intangible assets.

Year-to-date sales of \$1.7 billion increased \$0.9 billion reflecting the Danisco acquisition. PTOI of \$195 million was up \$165 million primarily reflecting benefits of the acquisition, realization of cost synergies and the absence of the \$33 million charge recorded in the prior year as described above. 2012 PTOI includes \$41 million of amortization expense associated with the fair value step-up of acquired intangible assets.

Performance Chemicals - Sales of \$2.0 billion were down 1 percent, with 10 percent lower volume partially offset by 9 percent higher selling prices. Higher selling prices more than offset higher ore costs. Lower volume reflects continued softness in titanium dioxide, particularly in Asia Pacific and Europe, and weakening demand in fluoropolymers. PTOI of \$538 million increased \$35 million on higher selling prices and continued productivity actions.

Year-to-date sales of \$3.9 billion were up 2 percent, with 13 percent higher selling prices partially offset by 11 percent lower volume. Higher selling prices more than offset higher ore costs. Lower volume primarily reflects continued softness in titanium dioxide, particularly in Asia Pacific. PTOI of \$1.1 billion increased \$0.2 billion on higher selling prices and continued productivity actions, partially offset by lower volume.

Performance Coatings - Sales of \$1.1 billion were down 1 percent, with 2 percent lower volume partially offset by 1 percent higher selling prices. Automotive builds were up 10 percent globally. OEM volume growth in North America and Asia Pacific was more than offset by lower refinish and powder coatings volume, particularly in European markets. Higher local selling prices across all regions and market segments were partially offset by the impact of unfavorable currency. PTOI of \$92 million increased \$19 million on higher selling prices, mix enrichment and continued productivity actions, partially offset by unfavorable currency.

Year-to-date sales of \$2.1 billion were up 2 percent with 3 percent higher selling prices partially offset by 1 percent lower volume. Higher local selling prices across all regions and market segments offset higher raw material costs and



the impact of unfavorable currency. Automotive builds were up globally. OEM volume growth in North America and Asia Pacific was more than offset by lower refinish and powder coatings volume, particularly in European markets. PTOI of \$179 million increased \$41 million on higher selling prices, mix enrichment and continued productivity actions, partially offset by unfavorable currency.

Performance Materials - Sales of \$1.7 billion were down 3 percent, primarily reflecting a 3 percent reduction from a portfolio change and 1 percent lower selling prices, partially offset by 1 percent higher volume. The lower selling prices were primarily the result of unfavorable currency. Volume growth in packaging markets and continued strong demand in the automotive market, particularly in North America, were partially offset by continued softness in the industrial and electronic markets, especially in Europe and Asia Pacific. PTOI of \$317 million increased \$63 million due to lower feedstock costs and higher volume, partially offset by unfavorable currency.

Table of Contents

Year-to-date sales of \$3.3 billion were down 4 percent, with 4 percent lower volume and a 2 percent reduction from a portfolio change partially offset by 2 percent higher selling prices. Continued strong demand in the automotive market, particularly in North America, was more than offset by softness in the industrial and electronic markets. PTOI of \$557 million increased \$15 million due to lower feedstock costs, partially offset by lower volume and unfavorable currency impact.

Safety & Protection - Sales of \$986 million were down 4 percent, with 5 percent lower volume partially offset by 1 percent higher selling prices. Volume declined due to lower public sector demand and continued softness in industrial markets. Higher local selling prices from value-based pricing were partially offset by the impact of unfavorable currency. PTOI of \$127 million decreased \$16 million on weaker mix, unfavorable currency and higher spending for growth initiatives primarily related to costs associated with operating the new Kevlar® aramids Cooper River plant. These decreases were partially offset by value-based pricing actions.

Year-to-date sales of \$1.9 billion were down 3 percent, with 5 percent lower volume partially offset by 2 percent higher selling prices. Volume declined due to lower public sector demand and continued softness in industrial markets. Higher local selling prices from value-based pricing were partially offset by the impact of unfavorable currency. PTOI of \$227 million decreased \$61 million on lower volume, unfavorable currency and higher costs associated with operating the Cooper River plant, partially offset by value-based pricing actions.

Pharmaceuticals - Second quarter PTOI was \$16 million compared to \$80 million in the same period last year. Year-to-date PTOI was \$43 million compared to \$130 million in the prior year. Decreased PTOI reflects the expiration of certain patents for Cozaar®/Hyzaar®.

## Liquidity &amp; Capital Resources

(Dollars in millions)	June 30, 2012	December 31, 2011
Cash, cash equivalents and marketable securities	\$3,556	\$4,019
Total debt	14,950	12,553

The company believes its ability to generate cash from operations and access to capital markets will be adequate to meet anticipated cash requirements to fund working capital, capital spending, dividend payments, debt maturities and other cash needs. The company's liquidity needs can be met through a variety of sources, including: cash provided by operating activities, cash and cash equivalents, marketable securities, commercial paper, syndicated credit lines, bilateral credit lines, equity and long-term debt markets and asset sales. The company's current strong financial position, liquidity and credit ratings provide excellent access to the capital markets. In addition, spending and capital productivity actions have been implemented. The company will continue to monitor the financial markets in order to respond to changing conditions. Depending on these conditions, the proceeds of commercial paper may be invested in cash equivalents or marketable securities.

Pursuant to its cash discipline policy, the company seeks first to maintain a strong balance sheet and second, to return excess cash to shareholders unless the opportunity to invest for growth is compelling. Cash, cash equivalents and marketable securities provide primary liquidity to support all short-term obligations. A substantial majority of the company's cash, cash equivalents and marketable securities is held by foreign subsidiaries and is considered to be indefinitely reinvested and expected to be utilized to fund local operating activities and capital expenditure requirements. The company believes that it has sufficient sources of domestic liquidity to further support its assumption that undistributed earnings at June 30, 2012 can be considered reinvested indefinitely. The company has access to approximately \$4.2 billion in unused credit lines with several major financial institutions, as additional support to meet short-term liquidity needs and general corporate purposes, including letters of credit.

The company continually reviews its debt portfolio and occasionally may rebalance it to ensure adequate liquidity and an optimum debt maturity schedule.

The company's credit ratings impact its access to the debt capital market and cost of capital. The company remains committed to a strong financial position and strong investment-grade rating. The company's long-term and short-term credit ratings are as follows:

	Long-term	Short-term	Outlook
Standard & Poor's	A	A-1	Stable
Moody's Investors Service	A2	P-1	Stable
Fitch Ratings	A	F1	Stable

Table of Contents

## Summary of Cash Flows

Cash used for operating activities was \$1.1 billion for the six months ended June 30, 2012 compared to cash used for operating activities of \$0.6 billion during the same period last year. The \$0.5 billion change was primarily due to a \$0.5 billion contribution to the U.S. pension plan.

Cash used for investing activities was \$0.1 billion for the six months ended June 30, 2012 compared to cash used for investing activities of \$5.0 billion for the same period last year. The \$4.9 billion change was primarily due to a decrease in payments for businesses acquired and proceeds rather than payments for settlements of forward exchange contracts, partially offset by lower proceeds from the sale of short-term financial instruments. Purchases of property, plant and equipment for the six months ended June 30, 2012 totaled \$696 million, a decrease of \$45 million compared to the same period last year.

Cash provided by financing activities was \$1.2 billion for the six months ended June 30, 2012 compared to cash provided by financing activities of \$3.5 billion for the same period last year. The \$2.3 billion difference was due primarily to lower proceeds from borrowings, higher payments for common stock repurchased, lower proceeds from stock options exercised and the purchase of the noncontrolling interest in the Solae, LLC joint venture.

(Dollars in millions)	Six Months Ended	
	June 30, 2012	2011
Cash used for operating activities	\$(1,117	)(644
Purchases of property, plant and equipment	(696	)(741
Free cash flow	\$(1,813	)(1,385

Free cash flow is a measurement not recognized in accordance with generally accepted accounting principles in the U.S. (GAAP) and should not be viewed as an alternative to GAAP measures of performance. All companies do not calculate non-GAAP financial measures in the same manner and, accordingly, the company's free cash flow definition may not be consistent with the methodologies used by other companies. The company defines free cash flow as cash provided by operating activities less purchases of property, plant and equipment, and therefore indicates operating cash flow available for payment of dividends, other investing activities and other financing activities. Free cash flow is useful to investors and management to evaluate the company's cash flow and financial performance, and is an integral financial measure used in the company's financial planning process.

Dividends paid to shareholders during the six months ended June 30, 2012 totaled \$788 million. In April 2012, the company's Board of Directors declared a second quarter common stock dividend of \$0.43 per share, a 5 percent increase. The second quarter dividend was the company's 43<sup>rd</sup> consecutive quarterly dividend since the company's first dividend in the fourth quarter 1904.

In February 2012, the company entered into an agreement with a financial institution and paid \$400 million for the purchase of shares of common stock. The shares were received and retired in May 2012. See Note 8 to the interim Consolidated Financial Statements for additional information.

## Guarantees and Off-Balance Sheet Arrangements

For detailed information related to Guarantees, Indemnifications, and Obligations for Equity Affiliates and Others, see page 31 of the company's 2011 Annual Report, and Note 7 to the interim Consolidated Financial Statements.

## Contractual Obligations

Information related to the company's contractual obligations at December 31, 2011 can be found on page 31 of the company's 2011 Annual Report. There have been no significant changes to the company's contractual obligations during the six months ended June 30, 2012.

PFOA

See discussion under “PFOA” on page 35 of the company's 2011 Annual Report and Note 7 to the interim Consolidated Financial Statements.

Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

See Note 9, “Financial Instruments”, to the interim Consolidated Financial Statements. See also Part II, Item 7A, Quantitative and Qualitative Disclosures About Market Risk, on pages 35 - 36 of the company's 2011 Annual Report for information on the company's utilization of financial instruments and an analysis of the sensitivity of these instruments.

Table of Contents

Item 4. CONTROLS AND PROCEDURES

a) Evaluation of Disclosure Controls and Procedures

The company maintains a system of disclosure controls and procedures to give reasonable assurance that information required to be disclosed in the company's reports filed or submitted under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission. These controls and procedures also give reasonable assurance that information required to be disclosed in such reports is accumulated and communicated to management to allow timely decisions regarding required disclosures.

As of June 30, 2012, the company's Chief Executive Officer (CEO) and Chief Financial Officer (CFO), together with management, conducted an evaluation of the effectiveness of the company's disclosure controls and procedures pursuant to Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Based on that evaluation, the CEO and CFO concluded that these disclosure controls and procedures are effective.

b) Changes in Internal Control over Financial Reporting

There has been no change in the company's internal control over financial reporting that occurred during the quarter ended June 30, 2012 that has materially affected or is reasonably likely to materially affect the company's internal control over financial reporting.

Table of Contents

PART II. OTHER INFORMATION

Item 1. LEGAL PROCEEDINGS

The company is subject to various litigation matters, including, but not limited to, product liability, patent infringement, antitrust claims, and claims for third party property damage or personal injury stemming from alleged environmental torts. Information regarding certain of these matters is set forth below and in Note 7 to the interim Consolidated Financial Statements.

Litigation

Imprelis® Herbicide Claims Process

Information related to this matter is included in Note 7 to the interim Consolidated Financial Statements under the heading Imprelis®.

PFOA: Environmental and Litigation Proceedings

For purposes of this report, the term PFOA means collectively perfluorooctanoic acid and its salts, including the ammonium salt and does not distinguish between the two forms. Information related to this matter is included in Note 7 to the interim Consolidated Financial Statements under the heading PFOA.

Environmental Proceedings

Belle Plant, West Virginia

The U.S. Environmental Protection Agency (EPA) is investigating three chemical releases at DuPont's Belle facility in West Virginia which occurred in January 2010. One of the releases involved the death of a DuPont employee after exposure to phosgene.

Chambers Works Plant, Deepwater, New Jersey

In 2010, the government initiated an enforcement action alleging that the facility violated recordkeeping requirements of certain provisions of the Clean Air Act (CAA) and the Federal Clean Air Act Regulations (FCAR) governing Leak Detection and Reporting and that it failed to report emissions of a compound from Chambers Works' waste water treatment facility under the Emergency Planning and Community Right-to-Know Act. The alleged non-compliance was identified by EPA in 2007 and 2009 following separate environmental audits. DuPont is in settlement negotiations with EPA and the Department of Justice (DOJ).

DeLisle Plant, Pass Christian, Mississippi

In June 2012, DuPont agreed to pay a penalty of \$117,000 to resolve allegations from the Mississippi Commission on Environmental Quality regarding opacity emissions, certification and compliance test requirements at the DeLisle facility.

LaPorte Plant, LaPorte, Texas

EPA conducted a multimedia inspection at the LaPorte facility in January 2008. DuPont, EPA and DOJ began discussions in the fall of 2011 relating primarily to the management of certain materials in the facility's wastewater treatment system. These negotiations continue.

Sabine Plant, Orange, Texas

In June 2012, DuPont received allegations related to a multimedia inspection that the EPA conducted at the Sabine facility in March 2009. DuPont, EPA and DOJ are in discussions relating to the management of materials in the facility's waste water treatment system, hazardous waste management and air emissions.

Yerkes Plant, Buffalo, New York

The government alleges that the facility violated recordkeeping requirements of certain provisions of the CAA and the FCAR governing Leak Detection and Reporting and that it failed to accurately report emissions under the Emergency Planning and Community Right-to-Know Act. The alleged non-compliance was identified by EPA in 2006 and 2010 following separate environmental audits. DuPont is in settlement negotiations with EPA and DOJ.

Federal Insecticide, Fungicide and Rodenticide Act (FIFRA)

On July 3, 2012, DuPont received a “notice of noncompliance and show cause” letter from EPA Region III for alleged violations of FIFRA related to product labeling and adverse effects reporting for Imprelis®.



Table of Contents

## Item 1A. RISK FACTORS

There have been no material changes in the company's risk factors from those disclosed in Part I, Item 1A, Risk Factors, in the company's 2011 Annual Report.

## Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

In June 2001, the company's Board of Directors authorized up to \$2.0 billion for repurchases of the company's common stock (2001 plan). In April 2011, the company's Board of Directors authorized up to \$2.0 billion for repurchases of the company's common stock (2011 plan).

In the first quarter 2012, the company entered into an agreement with a financial institution in which the company paid \$400 million for the purchase of shares of common stock which were received in the second quarter 2012. As a result, during the second quarter 2012, the company purchased and retired 7.8 million shares at an average price of \$51.43 per share in connection with this agreement. These purchases completed the 2001 plan and began purchases under the 2011 plan. Under the completed 2001 plan, the company purchased a total of 42.0 million shares at a cost of \$2.0 billion. Under the 2011 plan, the company has purchased 5.5 million shares at a total cost of \$0.3 billion as of June 30, 2012. There is no required completion date for the purchases under the 2011 plan.

The following table summarizes information with respect to the company's purchase of its common stock during the three months ended June 30, 2012:

Month	Total Number of Shares Purchased	Average Price Paid per Share	Total Number of Shares Purchased as Part of Publicly Announced Program	Approximate Value of Shares that May Yet Be Purchased Under the Program <sup>1</sup> (Dollars in billions)
May	7,777,894	\$51.43	7,777,894	\$1.7
Total	7,777,894		7,777,894	

<sup>1</sup> Represents approximate value of shares that may yet be purchased under the 2011 plan.

## Item 4. MINE SAFETY DISCLOSURES

Information regarding mine safety and other regulatory actions at the company's surface mine in Starke, Florida is included in Exhibit 95 to this report.

## Item 6. EXHIBITS

Exhibits: The list of exhibits in the Exhibit Index to this report is incorporated herein by reference.

Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

E. I. DU PONT DE NEMOURS AND COMPANY  
(Registrant)

Date: July 24, 2012

By: /s/ Nicholas C. Fanandakis

Nicholas C. Fanandakis  
Executive Vice President and  
Chief Financial Officer  
(As Duly Authorized Officer and  
Principal Financial and Accounting Officer)

Table of Contents

EXHIBIT INDEX

Exhibit Number	Description
3.1	Company's Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the company's Annual Report on Form 10-K for the year ended December 31, 2007).
3.2	Company's Bylaws, as last amended effective November 1, 2009 (incorporated by reference to Exhibit 3.2 to the company's Annual Report on Form 10-K for the year ended December 31, 2009).
4	The company agrees to provide the Commission, on request, copies of instruments defining the rights of holders of long-term debt of the company and its subsidiaries.
10.1*	The DuPont Stock Accumulation and Deferred Compensation Plan for Directors, as last amended effective January 1, 2009 (incorporated by reference to Exhibit 10.1 to the company's Annual Report on Form 10-K for the year ended December 31, 2008).
10.2*	Company's Supplemental Retirement Income Plan, as last amended effective June 4, 1996 (incorporated by reference to Exhibit 10.2 to the company's Annual Report on Form 10-K for the year ended December 31, 2011).
10.3*	Company's Pension Restoration Plan, as restated effective July 17, 2006 (incorporated by reference to Exhibit 10.3 to the company's Quarterly Report on Form 10-Q for the period ended June 30, 2011).
10.4*	Company's Rules for Lump Sum Payments, as last amended effective December 20, 2007 (incorporated by reference to Exhibit 10.4 to the company's Quarterly Report on Form 10-Q for the period ended June 30, 2011).
10.5*	Company's Stock Performance Plan, as last amended effective January 25, 2007 (incorporated by reference to Exhibit 10.5 to the company's Annual Report on Form 10-K for the year ended December 31, 2011).
10.6*	Company's Equity and Incentive Plan as amended and restated effective March 2, 2011 and approved by the company's shareholders on April 27, 2011 (incorporated by reference to pages B1-B15 of the company's Annual Meeting Proxy Statement dated March 18, 2011).
10.7*	Form of Award Terms under the company's Equity and Incentive Plan (incorporated by reference to Exhibit 10.8 to the company's Quarterly Report on Form 10-Q for the period ended March 31, 2009).
10.8*	Company's Retirement Savings Restoration Plan, as last amended effective June 1, 2011 (incorporated by reference to Exhibit 10.8 to the company's Quarterly Report on Form 10-Q for the period ended June 30, 2011).
10.9*	Company's Retirement Income Plan for Directors, as last amended January 2011 (incorporated by reference to Exhibit 10.9 to the company's Quarterly Report on Form 10-Q for the period ended March 31, 2012).



Table of Contents

Exhibit Number	Description
10.10*	Company's Management Deferred Compensation Plan, adopted on May 2, 2008, as last amended May 12, 2010 (incorporated by reference to Exhibit 10.11 to the company's Quarterly Report on Form 10-Q for the period ended June 30, 2010).
10.11*	Supplemental Deferral Terms for Deferred Long Term Incentive Awards and Deferred Variable Compensation Awards (incorporated by reference to Exhibit 10.15 to the company's Annual Report on Form 10-K for the year ended December 31, 2008).
12	Computation of Ratio of Earnings to Fixed Charges.
31.1	Rule 13a-14(a)/15d-14(a) Certification of the company's Principal Executive Officer.
31.2	Rule 13a-14(a)/15d-14(a) Certification of the company's Principal Financial Officer.
32.1	Section 1350 Certification of the company's Principal Executive Officer. The information contained in this Exhibit shall not be deemed filed with the Securities and Exchange Commission nor incorporated by reference in any registration statement filed by the registrant under the Securities Act of 1933, as amended.
32.2	Section 1350 Certification of the company's Principal Financial Officer. The information contained in this Exhibit shall not be deemed filed with the Securities and Exchange Commission nor incorporated by reference in any registration statement filed by the registrant under the Securities Act of 1933, as amended.
95	Mine Safety Disclosures.
101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Schema Document
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	XBRL Taxonomy Extension Label Linkbase Document
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document

---

\*Management contract or compensatory plan or arrangement required to be filed as an exhibit to this Form 10-Q.